A new vaccine for honeybees — the first approved for an insect in the United States — is nearing commercial use, but Minnesota's bee community sees little near-term relief for the threatened pollinators.
The vaccine aims at preventing American foulbrood, a bacterial disease that has decimated hives for over a century. But it doesn't address the host of other issues facing bees and the global food system that depends on them.
As a result, reaction in Minnesota — ranked sixth nationally for honey production — has been muted.
"American foulbrood rates in Minnesota are very, very low," said University of Minnesota entomologist Marla Spivak.
Spivak said the vaccine shows promise, however, particularly if it works on viruses and other bee diseases.
The U.S. Department of Agriculture gave the treatment conditional approval Dec. 29, according to Dalan Animal Health, the biotech company in Georgia that developed it.
The vaccine itself is made of dead bacterium that is fed to worker bees who, in turn, feed it to the queen bee, said Brendon Keiser, Dalan's head of operations. It goes into her ovaries and is passed to the young. It won't get into honey, he said.
The vaccine is undergoing field trials and won't be on the market until late spring at the earliest, according to Dalan.